Quintiles IMS Holdings, Inc. provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. The company’s Product Development segment offers project management and clinical monitoring services, including study design and operational planning, investigator/site recruitment, site and regulatory start up, patient recruitment, clinical monitoring, project management for conducting various multi-site trials, and late phase interventional services; and clinical trial support services comprising clinical data management, bio statistical, cardiac safety and ECG laboratory, safety and pharmacovigilance, and phase I clinical pharmacology services, as well as clinical trial, genomic, and bioanalytical laboratory services. This segment also provides strategic planning and design services for biomarkers, genomics, and personalized medicine, as well as offers model-based drug development and regulatory affairs services; and consulting services. Its Integrated Healthcare Services segment offers commercial services comprising contract sales, market entry/market exit, integrated channel management, patient engagement, and market access and commercialization consulting services; real-world late phase research services, such as observational studies, comparative effectiveness studies, and product and disease registry services; and communication and health engagement services, including digital patient, and brand and scientific communications services, as well as provides payer and provider solutions, and advisory services. Quintiles IMS Holdings, Inc. serves biopharmaceutical companies, including medical device and diagnostics companies. The company was formerly known as Quintiles Transnational Holdings Inc. and changed its name to Quintiles IMS Holdings, Inc. as a result of its merger with IMS Health Holdings, Inc. in October 2016. The company was founded in 1982 and is based in Durham, North Carolina.